XML 17 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue:    
Total revenue $ 38,429 $ 24,401
Operating costs and expenses:    
Cost of goods sold $ 3,401 $ 970
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 74,676 $ 54,902
Selling, general and administrative 30,779 49,603
Total operating costs and expenses 108,856 105,475
Loss from operations (70,427) (81,074)
Interest and other, net    
Interest expense (501) (633)
Interest income and other income (expenses), net (453) 3,165
Total interest and other, net (954) 2,532
Loss before income taxes (71,381) (78,542)
Provision for (benefit from) income taxes 134 (194)
Investment loss in unconsolidated variable interest entity (240) 0
Net loss $ (71,755) $ (78,348)
Net loss per share - basic and diluted $ (0.78) $ (0.89)
Weighted average number of common shares used to calculate net loss per share - basic and diluted 91,688 88,219
License Revenue [Member]    
Revenue:    
Total revenue $ 0 $ 0
Development and Other Revenue [Member]    
Revenue:    
Total revenue 14,587 19,446
Product Revenue, Net [Member]    
Revenue:    
Total revenue 15,362 4,955
Drug Product Revenue [Member]    
Revenue:    
Total revenue $ 8,480 $ 0